%PDF-1.4
%
97 0 obj
<>
endobj
94 0 obj
<>
endobj
166 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-07-06T09:28:55Z
2024-03-28T08:42:46-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T08:42:46-07:00
application/pdf
Heather
2005-221.aug
uuid:504d7043-1dd2-11b2-0a00-850927bd3700
uuid:504d7045-1dd2-11b2-0a00-5b0000000000
endstream
endobj
81 0 obj
<>
endobj
83 0 obj
<>
endobj
82 0 obj
<>
endobj
84 0 obj
<>
endobj
44 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 73 0 R/Type/Page>>
endobj
47 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 75 0 R/Type/Page>>
endobj
172 0 obj
[176 0 R]
endobj
173 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 57 736.1941 Tm
[(17.)-875.1 (Paleolog E. )17.7 (The therapeutic potential of )17.7 (TNF-alpha blockade in)]TJ
2.175 -1.25 Td
(rheumatoid arthritis. Expert Opin Investig Drugs 2003;12:1087-95.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Gof)17.7 (fe B, Cather JC. Etanercept: )54.8 (An overview)64.9 (. J )54.8 (Am )54.8 (Acad Dermatol)]TJ
0 Tc 2.175 -1.25 Td
[(2003;49 Suppl:S105-1)36.9 (1.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (den Broeder )54.8 (AA, Joosten LA, Saxne )17.7 (T)74 (, et al. Long term anti-tumour)]TJ
2.175 -1.25 Td
[(necrosis factor alpha monotherapy in rheumatoid arthritis: ef)17.7 (fect on)]TJ
0 -1.25 TD
(radiological course and prognostic value of markers of cartilage)Tj
T*
[(turnover and endothelial activation. )54.8 (Ann Rheum Dis 2002;61:31)36.8 (1-8.)]TJ
-2.175 -1.25 Td
[(20.)-875.1 (Schif)17.7 (f MH. Role of interleukin 1 and interleukin 1 receptor )]TJ
2.175 -1.25 Td
[(antagonist in the mediation of rheumatoid arthritis. )54.8 (Ann Rheum Dis)]TJ
0 Tc T*
(2000;59 Suppl 1:i103-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(21.)-875.1 (Dayer JM. Evidence for the biological modulation of IL-1 activity:)]TJ
2.175 -1.25 Td
(the role of IL-1Ra. Clin Exp Rheumatol 2002;20 Suppl 27:S14-20. )Tj
-2.175 -1.25 Td
[(22.)-875.1 (Hansen KE, Cush J, Singhal )54.8 (A, et al. )17.7 (The safety and ef)17.7 (ficacy of)]TJ
2.175 -1.25 Td
(leflunomide in combination with infliximab in rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 2004;51:228-32. )Tj
-2.175 -1.25 Td
[(23.)-875.1 (Patel S, Ber)17.7 (gen )17.7 (W)91.9 (, Kraemer )54.8 (A, Keenan GF)79.7 (. Ef)17.7 (ficacy and safety of)]TJ
2.175 -1.25 Td
(remicade \(infliximab\) plus arava \(leflunomide\) in rheumatoid)Tj
T*
[(arthritis \(RA\) [abstract]. )54.8 (Arthritis Rheum 2001;44 Suppl:S84.)]TJ
-2.175 -1.25 Td
[(24.)-875.1 (Perdriger )54.8 (A, Combe B, Kuntz JL, et al. )54.8 (A)-220.1 (French multicenter )]TJ
2.175 -1.25 Td
[(retrospective study on the ef)17.7 (ficacy and safety of infliximab in )]TJ
T*
[(association with DMARDs other than methotrexate [abstract]. )54.8 (Ann)]TJ
0 Tc T*
(Rheum Dis 2004;50 Suppl:488.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(25.)-875.1 (Godinho F)79.7 (, Godfrin B, El Mahou S, Navaux F)79.7 (, Zabraniecki L,)]TJ
2.175 -1.25 Td
[(Cantagrel )54.8 (A. Safety of leflunomide plus infliximab combination)]TJ
T*
(therapy in rheumatoid arthritis. Clin Exp Rheumatol )Tj
0 Tc 0 Tw T*
(2004;22:328-30. )Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(26.)-875.1 (Ortiz Garcia )54.8 (AM, Gonzalez-Alvaro I, Rosello Pardo R, Carmona L,)]TJ
2.175 -1.25 Td
(Fabregas Canales MD, Monteagudo Saez I. Infliximab and)Tj
T*
[(Leflunomide Study Group. Ef)17.7 (fectiveness and safety of infliximab)]TJ
T*
(combined with leflunomide in chronic polyarthritis [letter]. Clin)Tj
T*
(Exp Rheumatol 2004;22:790.)Tj
-2.175 -1.25 Td
[(27.)-875.1 (Struppler CI, )17.7 (Thies )17.7 (W)91.9 (, Schattenkirchner M, Kellner H. Safety and)]TJ
2.175 -1.25 Td
[(ef)17.7 (ficacy of leflunomide and infliximab in rheumatoid arthritis \(RA\))]TJ
0 Tc T*
[(patients [abstract]. )54.8 (Ann Rheum Dis 2002;61:S388.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(28.)-875.1 (Bingham SJ, Buch MH, Kerr MA, Emery P)110.7 (,)-0.1 ( )17.7 (V)110.8 (aladao Barcelos )54.8 (A)110.8 (T)74 (.)]TJ
2.175 -1.25 Td
(Induction of antinuclear antibodies in patients with rheumatoid)Tj
T*
[(arthritis treated with infliximab and leflunomide. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2004;50:4072-3.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(29.)-875.1 (Flendrie M, Creemers MC, )17.7 (W)79.9 (elsing PM, van Riel PL. )17.7 (The)]TJ
2.175 -1.25 Td
[(influence of previous and concomitant leflunomide on the ef)17.7 (ficacy)]TJ
T*
(and safety of infliximab therapy in patients with rheumatoid )Tj
T*
[(arthritis; a longitudinal observational study)64.8 (. Rheumatology Oxford)]TJ
0 Tc 0 Tw T*
(2005;44:472-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(30.)-875.1 (Antoni C, Manger B. )17.7 (T)35 (reatment of psoriatic arthritis with )17.7 (TNF)]TJ
2.175 -1.25 Td
(alpha-antagonists. Z Rheumatol 2003;62:235-9.)Tj
30.825 56.25 Td
[(31.)-875.1 (Furst DE, Schif)17.7 (f MH, Fleischmann RM, et al. )54.8 (Adalimumab, a fully)]TJ
2.175 -1.25 Td
[(human anti tumor necrosis factor)19.7 (-alpha monoclonal antibody)64.8 (, and)]TJ
T*
(concomitant standard antirheumatic therapy for the treatment of)Tj
T*
[(rheumatoid arthritis: results of ST)79.7 (AR \(Safety )17.7 (T)35 (rial of )54.8 (Adalimumab)]TJ
T*
[(in Rheumatoid )54.8 (Arthritis\). J Rheumatol 2003;30:2563-71.)]TJ
-2.175 -1.25 Td
[(32.)-875.1 (T)69.9 (esser J, Fleischmann R, Dore R, et al. Concomitant medication)]TJ
2.175 -1.25 Td
[(use in a lar)17.7 (ge, international, multicenter)39.7 (, placebo controlled trial of)]TJ
T*
(anakinra, a recombinant interleukin 1 receptor antagonist, in)Tj
T*
(patients with rheumatoid arthritis. J Rheumatol 2004;31:649-54.)Tj
-2.175 -1.25 Td
[(33.)-875.1 (De R)39.7 (ycke L, Peene I, Hof)17.7 (fman IE, et al. Rheumatoid factor and)]TJ
2.175 -1.25 Td
(anticitrullinated protein antibodies in rheumatoid arthritis: )Tj
T*
(diagnostic value, associations with radiological progression rate,)Tj
T*
[(and extra-articular manifestations. )54.8 (Ann Rheum Dis )]TJ
0 Tc 0 Tw T*
(2004;63:1587-93.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(34.)-875.1 (Garnero P)110.7 (, Landewe R, Boers M, et al. )54.8 (Association of baseline )]TJ
2.175 -1.25 Td
(levels of markers of bone and cartilage degradation with long-term)Tj
T*
(progression of joint damage in patients with early rheumatoid)Tj
T*
[(arthritis: the COBRA)-220.2 (study)64.8 (. )54.8 (Arthritis Rheum 2002;46:2847-56.)]TJ
-2.175 -1.25 Td
[(35.)-875.1 (de )17.7 (V)59.8 (ries-Bouwstra JK, Goekoop-Ruiterman )36.8 (YPM, )17.7 (V)110.8 (an Zeben D, et)]TJ
2.175 -1.25 Td
[(al. BeSt )17.7 (T)35 (rial Group. )54.8 (A)-220.1 (comparison of clinical and radiological )]TJ
T*
(outcomes of four treatment strategies for early rheumatoid arthritis:)Tj
T*
(results of the BeSt trial [abstract]. EULAR Meeting, Berlin,)Tj
T*
[(Germany)64.8 (, 2004: 0P0001. [Internet] )54.8 (Accessed )54.8 (April 14, 2005.)]TJ
T*
[(A)73.9 (vailable from)]TJ
0 Tw T*
[(http://www)64.8 (.eular)54.8 (.or)17.7 (g/index.cfm?framePage=/eular2004.cfm.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(36.)-875.1 (Klareskog L, van der Heijde D, de Jager JP)110.7 (, et al. )17.7 (Therapeutic ef)17.7 (fect)]TJ
2.175 -1.25 Td
(of the combination of etanercept and methotrexate compared with)Tj
T*
(each treatment alone in patients with rheumatoid arthritis: )Tj
T*
(double-blind randomized controlled trial. Lancet 2004;363:675-81.)Tj
-2.175 -1.25 Td
[(37.)-875.1 (W)79.9 (olfe F)79.7 (, Michaud K, Gefeller O, Choi HK. Predicting mortality in)]TJ
2.175 -1.25 Td
[(patients with rheumatoid arthritis. )54.8 (Arthritis Rheum )]TJ
0 Tc 0 Tw T*
(2003;48:1530-42.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(38.)-875.1 (Cunnane G, )17.7 (W)79.9 (arnock M, Fye KH, Daikh DI. )54.8 (Accelerated nodulosis)]TJ
2.175 -1.25 Td
(and vasculitis following etanercept therapy for rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 2002;47:445-9.)Tj
-2.175 -1.25 Td
[(39.)-875.1 (McCain ME, Quinet RJ, Davis )17.7 (WE. Etanercept and infliximab)]TJ
2.175 -1.25 Td
(associated with cutaneous vasculitis. Rheumatology Oxford)Tj
0 Tc 0 Tw T*
[(2002;41:1)36.9 (16-7.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(40.)-875.1 (Macdonald J, Zhong )17.7 (T)74 (, Lazarescu )54.8 (A, Gan BS, Harth M. )17.7 (V)110.8 (asculitis)]TJ
2.175 -1.25 Td
(associated with the use of leflunomide. J Rheumatol )Tj
0 Tc 0 Tw T*
(2004;31:2076-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(41.)-875.1 (Mockenhaupt M, Kelly JP)110.7 (, Kaufman D, Stern RS; SCAR Study)]TJ
2.175 -1.25 Td
[(Group. )17.7 (The risk of Stevens-Johnson syndrome and toxic epidermal)]TJ
T*
(necrolysis associated with nonsteroidal antiinflammatory drugs: a)Tj
T*
(multinational perspective. J Rheumatol 2003;30:2234-40.)Tj
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tc 0 Tw 8 0 0 8 541.468 56.4344 Tm
(1631)Tj
ET
0 0 0 0 k
53.532 70.503 203 -16.525 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 56.7125 Tm
(Kalden, et al: Leflunomide expert panel meeting)Tj
ET
0 0 0 0 k
/GS0 gs
104.631 82.383 407.5 -10.833 re
f*
0.5 w
/GS1 gs
104.631 82.383 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
75 0 obj
<>stream
8;Z\6$#[UF%.sQakjOajoc1mh!_T8g>)Q9L*$=52/=F]\Oi=M@muPfTlS(NB'qcg*27Ga/\Y7f<=3*sf@eQ^oM,"^DOq]>1F$_5tA*]7>sb-,m^'_BY'GW+NBa3/)2@
MhG+?lQZ/p"*uXsJppDEDp_Q3oFmBJZ@K=9d+s0XQOK*051G-]+g[\4?)1,0\pjV''<;0Ork1iO)Of8V6b7)B6Rk5e*/iBL[ac%\HG
moIt9SdW/(=J7NkF!_M^VD&*h+=a(X*^)9gQO3jpJ7RVH?:@G\q%B!;pjGp%?H,W=
jQmoDZ\FJ[VXM'dBh>7Fhfa^9`u%lM.<;(@@CoY&9Xefmr)9.m@fd6Ub&(/a,@XRN
4W8HtMrI\E%8FXLdO8Bp:1ufklA_jm`RaomreG*m`H*[q#S'IY;Uo5d]d;LVIOJJ9
*0/G9;Vc9/CE^9K-&8d`kQ,DdZSQP/3)'B6egkaeDs]eMl!073bPiLX/R,Z"fs524
re/6,2@]4oqRc%00:0n/I8Ju#%C9k_56Cm?H+fd~>
endstream
endobj
79 0 obj
[/Indexed/DeviceRGB 255 78 0 R]
endobj
78 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
110 0 obj
<>
endobj
103 0 obj
<>
endobj
141 0 obj
<>
endobj
171 0 obj
<>
endobj
106 0 obj
<>
endobj
135 0 obj
<>stream
HtTkPY6tGQa}#>Qy !Dy@Fc!8cB)躲[>g9T6ڭ[uֹusw&f-UZuIq
Nq.Պc53ΊcJ1G ~2v"谇LvqY)plS"/%~4r$h>'Il.ƨ-i$J+_$5IEro\{aO1,$&pX+flt~
b^XZ+KNdelsc).z|4'MB,W;aC,D#yMƑ3T3PUGw"ǏNaNW:?K;i^MoC?t~a)sC}wKʜHf"%zk!Oz!Q
< =Z/$6TE4!zscc8G|ր
9B=6")brzgVpFl~HlqJbGޒtUE{i-n\^UZZ#A*'%?dzcr
L1C
yR>wfHY
R{u d(P.ߡAN+Nv=`3#Ţ$<@t
qqnS%|
k~l'"u8͑gHN#Rl3YlVZʮo _0Zsb9[""Ǿz~j&
_
J>4d!BL]DB ݰOs;nPK~
8:Fx